1-(1-(3-(5-methoxy-2-methylphenoxy)-4-methylpentyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one | 478613-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(1-(3-(5-methoxy-2-methylphenoxy)-4-methylpentyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 3-[1-[3-(5-methoxy-2-methylphenoxy)-4-methylpentyl]piperidin-4-yl]-1H-benzimidazol-2-one
• CAS: 478613-34-2
• 化学式: C₂₆H₃₅N₃O₃
• 分子量: 437.582
• InChiKey: HDTXDTWVQLQAMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氯-3-氯甲基-1,2,4-噻二唑 、 1-(1-(3-(5-methoxy-2-methylphenoxy)-4-methylpentyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以61%的产率得到1-(5-氯-1,2,4-噻二唑-3-基甲基)-3-{1-[3-(5-甲氧基-2-甲基-苯氧基)-4-甲基-戊基]-哌啶-4-基}-1,3-二氢-苯并咪唑-2-酮
  参考文献：
  名称：

  N-3取代苯氧丙基哌啶苯并咪唑-2-酮类似物作为具有镇痛作用的NOP受体激动剂的结构活性关系和CoMFA。

  摘要：

  使用CoMFA模型的预测能力，优化了一系列3-苯氧基丙基哌啶苯并咪唑-2-一类似物的N-3位置。该模型用于对化合物进行优先排序，最终合成出三唑（+）-24。（+）-24被发现是一种高亲和力，强效的NOP激动剂，并在静脉内施用给啮齿动物后表现出抗伤害感受和抗痛觉过敏的作用。

  DOI：

  10.1016/j.bmc.2008.01.005
• 作为产物：
  描述：

  1-chloro-4-methyl-pentan-3-one 在 lithium aluminium tetrahydride 、 偶氮二甲酸二异丙酯 、 potassium carbonate 、 三苯基膦 、 sodium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(1-(3-(5-methoxy-2-methylphenoxy)-4-methylpentyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists

  摘要：

  A series of 3-phenoxypropyl piperidine analogues have been discovered as novel ORL1 receptor agonists. Structure-activity relationships have been explored around the 3-phenoxypropyl region with several potent and selective analogues identified. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.049

文献信息

• Asymmetric synthesis of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one derivatives, potent and selective NOP agonists
  作者：John K. Clark、Philip S. Jones、Ronald Palin、Georgina Rosair、Mark Weston

  DOI：10.1016/j.tet.2008.01.125

  日期：2008.3

  The asymmetric synthesis of the potent selective NOP agonist 2-(3-1-[3-(5-methoxy-2-methyl-phenoxy)-4-methyl-pentyl]-piperidin-4-yl}-2-oxo-2,3-dihydro-benzimidazol-1-yl)-N-methyl-acetamide and analogues was developed. The key step, chiral reduction of methyl isobutyryl acetate, was achieved using a mild Noyori-type asymmetric hydrogenation.

  有效的选择性NOP激动剂2-（3- 1- [3-（5-甲氧基-2-甲基-苯氧基）-4-甲基-戊基]-哌啶-4-基} -2-氧-的不对称合成开发了2，3-二氢苯并咪唑-1-基）-N-甲基-乙酰胺和类似物。关键步骤是使用温和的Noyori型不对称氢化实现手性还原乙酸甲基异丁酯。
• [EN] 1-(3-PHENYLOXYPROPYL)PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE 1-(3-PHENYLOXYPROPYL)PIPERIDINE
  申请人：AKZO NOBEL NV

  公开号：WO2002100861A1

  公开（公告）日：2002-12-19

  The present invention relates to 1(3-phenyloxypropyl)-piperidine derivative having general Formula (I), wherein R1 is (C1-6)alkyl or (C4-8)cycloalkyl or phenyl, optionally substituted with (C1-6)alkyl, (C1-6)alkyloxy or halogen; R2 is H or (C1-6)alkyl; or R1 and R2 form together with the carbon atom to which they are bound (C4-8)cycloalkyl, optionally substitutes with (C1-6)alkyloxy or halogen; R3 is H, OH, (C1-6)alkyloxy or (C1-6)alkylcarbonyloxy; R4 represents 1-5 substituents independently selected from H, (C1-6)alkyl, (C1-6)alkyloxy and halogen; Y represents (a), (b) and Z is H; or Y and Z together with the carbon atom to which they are bound represent the spiro atom in the spiro atom in the spiro system formed with (c) *represents the spiro carbon atom; R6 is H, (C1-6)alkyl or (CO)n-(CH2)m-R12; n is 0 or 1; m is 1-4; R8 and R10 are independently H or(C1-6)alkyl; R7, R9 and R11 are independently H, (C1-6)alkyl, (C1-6)alkyloxy or halogen; R12 is hydroxy, (C1-4)alkyloxy, (C1-4)alkylthio, (C1-4)alkyloxycarbonyl, (C1-4)alkylcarbonyloxy, 2-tetrahydrofuranyl, 4-morpholinyl or di(C1-4)alkylamino; or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 1-(3-phenyloxypropyl)-piperidine derivatives in therapy.